

## APC Human EphA2 Protein (C-His)

<b>Catalog Number:</b>	814503, 814504
<b>Size:</b>	25 ug, 100 ug
<b>Target Name:</b>	EphA2
<b>Regulatory Status:</b>	RUO

### PRODUCT DETAILS

---

<b>Application:</b>	Flow Cytometry
<b>Format:</b>	Liquid, APC
<b>Expression Host:</b>	CHO
<b>Species:</b>	Human
<b>Sources:</b>	Recombinant Human EphA2 (Gln25-Asn534) with C-terminus His-tag is expressed in CHO cell and conjugated to APC.
<b>Accession Number:</b>	P29317
<b>Molecular Weight:</b>	The protein has a predicted molecular weight of 57.7 kDa. Under DTT-reducing conditions, it migrates at approximately 60 kDa on SDS-PAGE prior to conjugation.
<b>Affinity Tag:</b>	C-His
<b>Formulation:</b>	1xPBS buffer, pH7.4, 0.09% NaN3 with a carrier protein
<b>Endotoxin level:</b>	Not tested
<b>Protein Concentration:</b>	25µg size is bottled at 0.1mg/mL concentration. 100 µg size is bottled at lot specific concentration.
<b>Storage and Handling:</b>	Briefly centrifuge the vial upon receipt. An unopened vial may be stored at 2-8°C for up to six months.

### BACKGROUND INFORMATION

---

EphA2 (Ephrin type-A receptor 2) is a receptor tyrosine kinase involved in cell adhesion, migration, and tissue organization. It plays a critical role in embryonic development and angiogenesis. EphA2 is frequently overexpressed in various cancers, including breast, lung, and prostate cancer. Overexpression is associated with increased tumor growth, invasiveness, and poor clinical outcomes. Because of its role in promoting tumor progression, EphA2 is being actively explored as a therapeutic target in oncology. Therapeutic strategies include monoclonal antibodies, small molecule inhibitors, and antibody-drug conjugates targeting EphA2-positive tumors.